Related Experiment Videos
Systematic analysis of the TGF-beta-Smad signaling pathway in gastrointestinal cancer cells
1Department of Gastroenterology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. ijichi-2im@h.u-tokyo.ac.jp
Abstract:
The transforming growth factor-beta (TGF-beta)-Smad signaling pathway has an important role in carcinogenesis. To study the frequency and mechanism of functional impairment of this pathway in human gastrointestinal cancers, we used a reporter assay to examine the response of 38 cell lines (11 colorectal, 9 pancreatic, 10 gastric, and 8 hepatic cancers) to TGF-beta. We then analyzed TGF-beta type II receptor (T beta RII) gene, immunoblots of Smad4, and restoration of the pathway by rescuing T beta R or Smad. We observed impaired signaling in 91% of colorectal, 67% of pancreatic, and 40% of gastric cancer cell lines, but in none of the hepatic cancer cells. We suggest that this pathway does not function as a tumor suppressor in hepatic carcinogenesis. The impairment is due to inactivation of T beta RII and Smad4 in colorectal and pancreatic cancers. However, because the signal was not recovered by rescuing T beta R or Smad genes in TGF-beta-response-defective gastric cancer cell lines, we suggest that novel molecules or mechanisms are involved in the impaired pathway in some gastric cancers.
Insights
The transforming growth factor-beta (TGF-beta) pathway is frequently impaired in colorectal, pancreatic, and gastric cancers, often due to T beta RII and Smad4 inactivation. This pathway does not appear to be a tumor suppressor in liver cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- The transforming growth factor-beta (TGF-beta)-Smad signaling pathway plays a critical role in cellular processes relevant to cancer.
- Understanding the functional status of this pathway is crucial for identifying therapeutic targets in various malignancies.
Purpose of the Study:
- To investigate the frequency and mechanisms of functional impairment of the TGF-beta-Smad pathway in human gastrointestinal cancers.
- To determine if the TGF-beta-Smad pathway acts as a tumor suppressor in hepatic carcinogenesis.
Main Methods:
- Utilized a reporter assay to assess TGF-beta responsiveness in 38 cancer cell lines (colorectal, pancreatic, gastric, hepatic).
- Analyzed TGF-beta type II receptor (T beta RII) gene status, Smad4 protein levels via immunoblotting, and pathway restoration through gene rescue experiments.
Main Results:
- Impaired TGF-beta signaling was observed in 91% of colorectal, 67% of pancreatic, and 40% of gastric cancer cell lines.
- Hepatic cancer cell lines showed no impairment, suggesting the pathway is not a tumor suppressor in liver cancer.
- In colorectal and pancreatic cancers, impairment was linked to T beta RII and Smad4 inactivation.
- In gastric cancers with impaired signaling, pathway restoration was not achieved by rescuing T beta R or Smad genes.
Conclusions:
- The TGF-beta-Smad pathway is frequently dysfunctional in gastrointestinal cancers, particularly colorectal and pancreatic.
- Inactivation of T beta RII and Smad4 are key mechanisms of impairment in colorectal and pancreatic cancers.
- Novel molecules or mechanisms likely contribute to impaired TGF-beta signaling in some gastric cancers, warranting further investigation.